AZD5718 was well tolerated in healthy Japanese subjects.

The pharmacokinetics and pharmacodynamics in healthy Japanese subjects were similar to those reported in non-Japanese healthy subjects.

The study results support the development of similar doses of AZD5718 in Japanese and non-Japanese coronary artery disease and chronic kidney disease patients.